Analysts Set Prothena Corporation plc (NASDAQ:PRTA) Target Price at $19.75

Prothena Corporation plc (NASDAQ:PRTA) has earned a consensus recommendation of “Hold” from the nine ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $19.75.

A number of research firms recently commented on PRTA. Jefferies Financial Group lowered Prothena from a “buy” rating to a “hold” rating and set a $6.00 price target for the company. in a research report on Tuesday, May 27th. Royal Bank Of Canada lowered their target price on shares of Prothena from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Tuesday, August 5th. Oppenheimer cut shares of Prothena from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 27th. JMP Securities decreased their price objective on shares of Prothena from $29.00 to $11.00 and set a “market outperform” rating for the company in a research note on Tuesday, September 2nd. Finally, HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Prothena in a research report on Tuesday, August 5th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Prothena by 6.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,269 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 1,551 shares during the period. Purkiss Capital Advisors LLC increased its holdings in Prothena by 15.1% during the second quarter. Purkiss Capital Advisors LLC now owns 24,904 shares of the biotechnology company’s stock worth $151,000 after buying an additional 3,275 shares during the last quarter. ProShare Advisors LLC raised its position in Prothena by 29.5% in the fourth quarter. ProShare Advisors LLC now owns 14,524 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 3,312 shares during the period. Chicago Partners Investment Group LLC boosted its stake in Prothena by 29.6% in the first quarter. Chicago Partners Investment Group LLC now owns 14,512 shares of the biotechnology company’s stock valued at $180,000 after acquiring an additional 3,315 shares during the last quarter. Finally, Nordea Investment Management AB boosted its stake in Prothena by 1.2% in the second quarter. Nordea Investment Management AB now owns 311,605 shares of the biotechnology company’s stock valued at $1,916,000 after acquiring an additional 3,618 shares during the last quarter. Institutional investors own 97.08% of the company’s stock.

Prothena Price Performance

PRTA opened at $8.31 on Monday. Prothena has a fifty-two week low of $4.32 and a fifty-two week high of $22.71. The firm has a market capitalization of $447.33 million, a PE ratio of -1.47 and a beta of -0.04. The company’s 50-day moving average is $7.45 and its 200 day moving average is $8.66.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported ($1.86) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.75). Prothena had a negative return on equity of 62.17% and a negative net margin of 2,929.30%.The company had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. As a group, analysts expect that Prothena will post -4.04 EPS for the current year.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.